Lisinopril for kidneys
Searched over 200M research papers
Summary
10 papers analyzed
These studies suggest that lisinopril can effectively reduce kidney function decline, albuminuria, and proteinuria in patients with diabetic nephropathy and other chronic renal diseases, while also having specific renoprotective effects beyond blood pressure control.
Not a yes or no question
To use the Consensus Meter, try asking a simple yes or no question
Research summarized with Copilot
Beta20 papers analyzed
Lisinopril for Kidney Health: A Comprehensive Review
Introduction to Lisinopril and Kidney Function
Lisinopril, an angiotensin-converting enzyme (ACE) inhibitor, is widely used to manage hypertension and heart failure. Its role in protecting kidney function, particularly in patients with diabetic nephropathy and other chronic kidney diseases, has been extensively studied. This article synthesizes findings from multiple research studies to provide a clear understanding of the effects of lisinopril on kidney health.
Lisinopril in Diabetic Nephropathy
Comparative Studies with Atenolol
Several studies have compared the effects of lisinopril with other antihypertensive agents like atenolol in patients with diabetic nephropathy. One study involving hypertensive non-insulin-dependent diabetes mellitus (NIDDM) patients found that both lisinopril and atenolol effectively reduced blood pressure and slowed the decline in glomerular filtration rate (GFR). However, lisinopril significantly reduced urinary albumin excretion, indicating better renal protection . Another study confirmed these findings, showing that lisinopril reduced albuminuria more effectively than atenolol, despite similar blood pressure reductions.
Long-Term Effects in Type 1 Diabetic Patients
In a long-term study involving type 1 diabetic patients with diabetic nephropathy, lisinopril was compared with the calcium antagonist nisoldipine. Both drugs showed similar benefits in slowing the progression of kidney disease over four years. However, lisinopril was more effective in reducing albuminuria, suggesting a superior renoprotective effect.
Lisinopril in Non-Diabetic Kidney Diseases
Mild Proteinuric Non-Diabetic Nephropathies
Lisinopril has also been studied in patients with non-diabetic chronic kidney diseases. In a study involving patients with mild proteinuria, lisinopril was more effective than other antihypertensive agents in slowing the progression of renal insufficiency. The study highlighted that lisinopril's renoprotective effects were independent of its blood pressure-lowering capabilities.
Renal Transplant Patients
In renal transplant patients with chronic allograft nephropathy, lisinopril was found to reduce proteinuria and preserve graft function over a year. The study concluded that lisinopril did not adversely affect the rate of decline in graft function and suggested that it might offer additional benefits in managing chronic allograft nephropathy.
Combination Therapies
ACE Inhibitors and ARBs
The combination of ACE inhibitors like lisinopril with angiotensin-receptor blockers (ARBs) has been explored for enhanced renal protection. However, a study on patients with diabetic nephropathy found that combination therapy increased the risk of adverse events such as hyperkalemia and acute kidney injury, without significant benefits in slowing disease progression compared to monotherapy.
Lisinopril and GLP-1R Agonists
Recent research has investigated the combined use of lisinopril and glucagon-like peptide-1 receptor (GLP-1R) agonists like semaglutide in diabetic kidney disease. The combination showed promising results in reducing blood pressure, albuminuria, and kidney injury markers, suggesting potential benefits of this therapeutic approach.
Conclusion
Lisinopril has demonstrated significant renoprotective effects in both diabetic and non-diabetic kidney diseases. It effectively reduces albuminuria and slows the progression of renal insufficiency, making it a valuable option in managing chronic kidney conditions. While combination therapies with ARBs may pose risks, combining lisinopril with GLP-1R agonists shows potential for enhanced kidney protection. Further research is needed to optimize treatment strategies and improve outcomes for patients with chronic kidney diseases.
Sources and full results
Most relevant research papers on this topic
